Raymond James & Associates Has $3.98 Million Stock Position in TG Therapeutics, Inc. (NASDAQ:TGTX)

Raymond James & Associates lifted its position in TG Therapeutics, Inc. (NASDAQ:TGTX) by 35.9% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 170,160 shares of the biopharmaceutical company’s stock after buying an additional 44,972 shares during the quarter. Raymond James & Associates’ holdings in TG Therapeutics were worth $3,980,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds have also modified their holdings of the company. Opaleye Management Inc. lifted its stake in shares of TG Therapeutics by 2.9% in the first quarter. Opaleye Management Inc. now owns 2,280,000 shares of the biopharmaceutical company’s stock worth $34,679,000 after buying an additional 65,000 shares during the last quarter. Marshall Wace LLP acquired a new stake in shares of TG Therapeutics in the second quarter worth $36,501,000. Hood River Capital Management LLC lifted its stake in shares of TG Therapeutics by 6.7% in the second quarter. Hood River Capital Management LLC now owns 1,572,929 shares of the biopharmaceutical company’s stock worth $27,982,000 after buying an additional 98,892 shares during the last quarter. Point72 Asset Management L.P. acquired a new stake in shares of TG Therapeutics in the second quarter worth $10,423,000. Finally, Jacobs Levy Equity Management Inc. lifted its stake in shares of TG Therapeutics by 29.9% in the first quarter. Jacobs Levy Equity Management Inc. now owns 524,861 shares of the biopharmaceutical company’s stock worth $7,983,000 after buying an additional 120,699 shares during the last quarter. 58.58% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of brokerages have recently weighed in on TGTX. The Goldman Sachs Group boosted their price objective on shares of TG Therapeutics from $18.00 to $20.00 and gave the stock a “neutral” rating in a research note on Wednesday, August 7th. HC Wainwright reiterated a “buy” rating and set a $49.00 target price on shares of TG Therapeutics in a research note on Wednesday, September 18th. TD Cowen initiated coverage on shares of TG Therapeutics in a research note on Tuesday, October 29th. They set a “buy” rating and a $50.00 target price for the company. Finally, B. Riley upped their target price on shares of TG Therapeutics from $29.00 to $34.00 and gave the company a “buy” rating in a research note on Wednesday, August 7th. Two equities research analysts have rated the stock with a hold rating and five have given a buy rating to the company. Based on data from MarketBeat, TG Therapeutics presently has an average rating of “Moderate Buy” and a consensus target price of $36.33.

TG Therapeutics Trading Up 7.3 %

Shares of TG Therapeutics stock opened at $26.90 on Monday. The firm has a market capitalization of $4.16 billion, a PE ratio of 44.10 and a beta of 2.19. The company has a debt-to-equity ratio of 0.58, a current ratio of 3.58 and a quick ratio of 2.83. The company’s fifty day moving average price is $23.51 and its two-hundred day moving average price is $20.05. TG Therapeutics, Inc. has a 52-week low of $9.81 and a 52-week high of $26.99.

TG Therapeutics (NASDAQ:TGTX) last announced its quarterly earnings results on Tuesday, August 6th. The biopharmaceutical company reported $0.04 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.04) by $0.08. The firm had revenue of $73.47 million for the quarter, compared to analyst estimates of $65.92 million. TG Therapeutics had a net margin of 27.60% and a return on equity of 57.73%. The business’s revenue for the quarter was up 357.0% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($0.34) EPS. On average, analysts expect that TG Therapeutics, Inc. will post 0.13 EPS for the current year.

TG Therapeutics Company Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.